Background: Rosacea is a chronic inflammatory dermatosis, frequently associated to various gastrointestinal disorders. Recent studies suggest that intestinal alkaline phosphatase, an enzyme that guards intestinal homeostasis might be involved in the pathogenesis of rosacea. Objective: The objective of this study is to investigate serum intestinal alkaline phosphatase -(IAP) enzymatic activity levels in rosacea patients and correlate them with different clinical forms. Methods: Twenty six rosacea patients and twenty three age -and sex-matched healthy controls were included in our study. The severity of rosacea was assessed according to the National Rosacea Society classification system. The levels of serum IAP enzymatic activity were measured in all individuals. Results: There was no statistically significant difference between IAP enzymatic activity levels in the patient and control group, but we demonstrated a significant difference (p<0.05) when comparing patients with papulopustular rosacea to healthy controls and also when comparing patients younger than 40 years to matched controls younger than 40 years. Conclusion: Our results suggest that increasing IAP enzymatic activity especially in papulopustular rosacea by special diet or by IAP supplementation might be beneficial in controlling this disease.
INTRODUCTION INTRODUCTION
Rosacea is a common chronic inflammatory facial dermatosis. Although in general rosacea affects young adults in their thirties to fifties with phototype II or III sun sensitive skin any person regardless of skintype or age can develop flushing with diffuse erythema, telangiectasia anda papulopustular eruption, namely the clinical signs specific to rosacea. In the medical literature, rosacea lesions have been reported even in children or in individuals of African descent. The prevalence of the disease in Europe is highly variable; in some countries upto one person in five presents rosacea. It affects women more than men, but the most severe cases appear in males (1) . According to the grading system of rosacea, published by the National Rosacea Society in The United States of America in 2002, rosacea has four distinct clinical forms: erythematotelangiectatic (RET), papulopustular (RPP), phymatous and ocular (2) . Telangiectasia, diffuse erythema and local burning sensation prevail in RET; inflammation with oedema, papules and pinpoint pustules are the hallmark in PPR, while in phymatous rosacea hyperplasia and hypertrophy of sebaceous glands on the nose, chin or less often ears are noticeable. In ocular rosacea patients have mainly ocular signs and symptoms, such as conjunctivitis, blepharitis, conjunctival telangiectasia, dryness or light irritation. Different types of lesions can be present simultaneously in one patient, but the lesion that clinically dominates is important for classifying the disease. Usually, in the evolution of the disease some of the existing clinical features accentuate graduall yor new ones emerge. The latest clinical classifications include uncommon variants of rosacea: granulomatous rosacea, neurogenic rosacea (3, 4) .
Despite the fact that so many people suffer from rosacea, studies proving that the impact rosacea has on the patient quality of life is similar to psoriasis (5), and that ample research has been done in all aspects of rosacea, scientists still did not succeed to clearly establish the etiology of this condition. Several etiopathogenic hypotheses regarding either local cutaneous anomalies or various infectious microorganisms have been proposed. Presently, it is postulated that vasculature and neuroimmune local dysregulations, dermal matrix degeneration, excessive oxidative stress due to high levels of reactive oxygen species, and abnormally high levels of antimicrobial peptides such as cathelicidins expressed in the skin all play central roles in rosacea development (6) . Various studies also proved that pathogens such as Demodex mites, Bacillus oleronius or Helicobacter pylori might be important in initializing the cascade of events that lead to cutaneous inflammation, the pathogenic basis of rosacea (7, 8) .
It appears that there is a strong link between the skin and the gut microbiota. Dysregulation of the bacterial population resident in the stomach or in the small intestine and certain infectious agents are responsible for gastrointestinal conditions that are described as possible comorbidities for rosacea: chronic gastritis, ulcerative colitis or Crohn's disease (some scientists imply that a not yet identified infectious microorganism might be the cause for these inflammatory bowel diseases) (9, 10) . In addition rosacea flare-ups can be triggered by certain types of food or beverages, some of which also modulate the activity of intestinal alkaline phosphatase (IAP) (11) . IAP is an enzyme localized in the brush border of the intestine with several protective functions. It has complex roles in maintaining gastrointestinal homeostasis and in blocking the inflammatory response triggered by pathogenic bacteria. IAP is involved in detoxification of drugs, heavy metals or foods, in regulating the intestinal surface pH and the passage of vasoactive peptides released into the intestinal lumen, through the intestinal brush border into the blood stream (12) . Hormones such as gastrin, vasoactive intestinal peptide (VIP) and secretin have potent vasodilator properties and are known rosacea triggers. In IAP functional disturbances, dilators have free pathway into the blood and determine worsening of rosacea symptoms (11) .
Recent studies showed that IAP might be the missing link to the influence some gastrointestinal conditions or dietary factors have on rosacea development and evolution (11) . Therefore we conducted the present study to investigate this possible relationship between rosacea and IAP by evaluating IAP enzymatic activity in rosacea patients.
METHODES METHODES
We recruited anumber of 49 human subjects for our experiment (26 rosacea patients and 23 healthy matched controls). Rosacea was diagnosed based on clinical signs and symptoms. We divided our patient group in 2 subgroups, in accordance with the form of rosacea: erythematotelangiectatic rosacea (RET) subgroup (15 patients) and papulopustular rosacea (RPP) subgroup (11 patients). None of the individuals had any systemic treatment or gastrointestinal symptom for the last two months previous to sample collection. Each included subject signed a written informed consent.
In order to evaluate IAP enzymatic activity, a 10 ml fasting blood sample was collected from each person within our study population. Each sample was immediately centrifuged at 1500 rpm, followed by electrophoresis and analysis of enzymatic activity in separate fractions. The results were expressed as µmol/sl and after ward converted in IU/L (commonly used value), using the standard conversion factor.
The statistical methodology used F-test for differences in variances, t-test for differences in means and histograms.
RESULTS RESULTS
Our patient group included 17 women with an age range of 21-75 years (mean age 39.58) and 9 men with Study of Serum Intestinal Alkaline Phosphatase in Rosacea an age range of 19-69 years (mean age 53.22). Sex ratio was approximately 2:1. The two mean ages correlate with patients'general behaviour: women seek medical examination at the onset of their disease while men ask medical advice in later, more severe stages. The control group was comparable in terms of sex (17 women, 7 men) and age (women age range 24-68 years, mean age 41.64; men age range 24-66 years, mean age 47.42) to the patient group.
All individuals had total alkaline phosphatase alkaline enzymatic activity within normal reference range (30-120 IU/L). Values for intestinal alkaline phosphatase enzymatic activity did not exceed 15% of the total alkaline phosphatase value (as considered normal by the laboratory performing the analysis) (13), except one higher value obtained in one control who was referred to gastroenterology. The above mentioned subject was excluded from our study, therefore 48 individuals were observed for this study.
In the rosacea group IAP activity values were normal in relation to total AP and varied from a minimum of 0.00 IU/L to a maximum of 11.38 IU/L (mean value 2.1 IU/L). In the control group values varied from a minimum of 0.0 IU/L to a maximum of 14.97 IU/L (mean value 3.78 IU/L) (table 1, fig. 1 ).
After we rejected the hypothesis that the variances of the two samples are equal (F-test, p = 0.03), we tested for differences in the means of the patient and control samples. We found no statistically significant differences between IAP levels in the patient (M = 3.78; SD = 4.76) and control groups (M =2.1; SD = 3.26): t(36) = 1.40, p = 0.085 for one-tail test. However, as the combined histogram from fig. 2 shows, it appears that lower values are more frequent in patients than in controls. The t-test methodology was repeated in the RET (15 patients) and RPP (11 patients) subgroups. The difference was not statistically significant when the RET subgroup was compared with the controls. In the case of the RPP subgroup, we found evidence for different means with the t-test t(31) = 2.05, p = 0.024. As confirmed by the histograms, the difference between IAP values from controls is less clear in RET patients, but in the case of the RPP subgroup we notice that patients more often have smaller IAP values (fig. 3) .
IAP levels were not affected by gender in either patient or control group. Then we investigated whether the age could play a significant role in the distribution of IAP values. The scatter plot of IAP levels against age ( fig. 4) shows that there appear to be a positive correlation in the case of patients and a negative one in the case of controls.
We detected a significant difference, t(13) = 1.85, p-value = 0.043 for one-tail t-test, assuming unequal variances,between IAP levels in rosacea patients younger than 40 years versus matched controls younger than 40 years ( fig. 5) . In this patient group we notice a higher distribution of 0.0 IU/L IAP activity value and of small values of IAP, IAP activity being significantly lower in rosacea patients. The 40 years threshold was chosen because in scientific literature in majority of patients this disease debuts after the age of 30 and up to 50 years (14) and because in our study population median age was close to 40 (43 years) l. Thus, the age of 40 could be a relevant threshold, because it assures that our study can find a reasonable sample size of patients while being as close as possible to the age interval that is characteristic for rosacea, i.e., after 30 years. 
DISSCUSION DISSCUSION
The results of our study reveal that overall there is a slight but no statistically significant difference between IAP activity value in patients versus healthy controls. We observed that we have fewer individuals with no detectable IAP in our control group: 10 healthy individuals compared to 14 patients (6 with RET and 7 with RPP) had IAP enzymatic activity value 0.00 UI/L. We also noticed fewer matched controls with small IAP values. In addition the highest normal values were distributed in the control group (13.17; 13.77; 14.97 IU/L). The subsample test that separated the rosacea patients according to their form of disease, indicated a significant difference in IAP mean enzymatic activity levels between patients diagnosed with papulopustular rosacea and the control group.
These findings suggest that IAP might have reduced activity in patients with inflammatory papulopustular rosacea and might play a role in its pathogenesis.
On the other hand, IAP values are significantly lower in those under 40 years of age, within the patient group compared to IAP values within the control group. In these patients IAP activity is lower and taking into account the fact that in adult population IAP activity does not differ between age groups (15) , it supports the idea that IAP is important in rosacea evolution inyoung adults. A possible explanation might be that young people nowadays have a more chaotic lifestyle with an irregular and unbalanced diet, based onhighly processed foods and low in fresh vegetables, inducing an acidic pH in the intestine which inhibits IAP function. This coupled with a genetic predisposition to rosacea, which now we know it is real (16), might promote rosacea onset. Further studies on larger study groups need to be conducted in order to confirm our results and to assess if IAP is involved in late onset rosacea.
CONCLUSION CONCLUSION
It appears that IAP might have a certain degree of influence in rosacea, especially in severe cases andin young adults in whom our study indicates that this enzyme has low activity. There might be also importance in studying if any therapeutically valuable result would be obtained in IAP supplementation in a subset of rosacea patients. So far, IAP administered intravenously has been successful in adjuvant therapy of necrotizing enterocolitis in neonates and sepsis in adults, by attenuation of the systemic inflammatory response and administered orally in moderate to severe ulcerative colitis, which led to short term improvement of the diseases (17) (18) (19) . Patients with RPP could modify their diet, including more alkalizing foods in order to stimulate IAP enzyme function. A healthy IAP activity will prevent intestinal hormones or peptides from entering the bloodflow with its consequent increase in local cutaneous inflammation and vasodilation. We could debate that by mitigating inflammation in people affected by rosacea, administered IAP would be beneficial for these patients, but this hypothesis needs to be further evaluated. In addition larger study groups might be useful to definitely establish if IAP plays or not a main role in rosacea development, regardless of age.
